AstraZeneca gets a much-needed boost for blood thinner Brilinta with an OK on stroke
While AstraZeneca’s blood thinner Brilinta is far from reaching its once-projected $3.5 billion sales peak in cardiovascular disease, a new approval allows the pharma giant to tap into the acute ischemic stroke (AIS) market for a boost.
The FDA gave Brilinta the official OK for use in mild-to-moderate stroke patients, based on results from the Phase III THALES study. The trial enrolled more than 11,000 patients in 28 countries, and measured the effects of Brilinta and aspirin compared to aspirin alone in patients with AIS or transient ischemic attack.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.